EA200970211A1 - Применение производных азабициклогексана - Google Patents

Применение производных азабициклогексана

Info

Publication number
EA200970211A1
EA200970211A1 EA200970211A EA200970211A EA200970211A1 EA 200970211 A1 EA200970211 A1 EA 200970211A1 EA 200970211 A EA200970211 A EA 200970211A EA 200970211 A EA200970211 A EA 200970211A EA 200970211 A1 EA200970211 A1 EA 200970211A1
Authority
EA
Eurasian Patent Office
Prior art keywords
azabicologogexane
derivatives
application
methyl
oxazol
Prior art date
Application number
EA200970211A
Other languages
English (en)
Other versions
EA017917B1 (ru
Inventor
Клер Луиз Андертон
Серджо Бакки
Стефания Беато
Франко Сартор
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37081324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200970211(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2006/008314 external-priority patent/WO2007022980A1/en
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of EA200970211A1 publication Critical patent/EA200970211A1/ru
Publication of EA017917B1 publication Critical patent/EA017917B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к тартратной соли 1-[2-фтор-4-(трифторметил)фенил]-3-(3-{[4-метил-5-(4-метил-1,3-оксазол-5-ил)-4Н-1,2,4-триазол-3-ил]тио)пропил)-3-азабицикло[3.1.0]гексана и ее сольватам, фармацевтическим композициям, способам для их получения и их применению в медицине.
EA200970211A 2006-08-21 2007-08-20 Применение производных азабициклогексана EA017917B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2006/008314 WO2007022980A1 (en) 2005-08-22 2006-08-21 Use of azabicyclo hexane derivatives
GBGB0616574.0A GB0616574D0 (en) 2006-08-21 2006-08-21 Compounds
PCT/EP2007/058636 WO2008022994A1 (en) 2006-08-21 2007-08-20 Use of azabicyclo hexane derivatives

Publications (2)

Publication Number Publication Date
EA200970211A1 true EA200970211A1 (ru) 2009-08-28
EA017917B1 EA017917B1 (ru) 2013-04-30

Family

ID=37081324

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970211A EA017917B1 (ru) 2006-08-21 2007-08-20 Применение производных азабициклогексана

Country Status (22)

Country Link
US (1) US20080058398A1 (ru)
EP (1) EP2054054A1 (ru)
JP (1) JP5315244B2 (ru)
KR (1) KR101495362B1 (ru)
CN (1) CN101528221B (ru)
AR (1) AR062471A1 (ru)
AU (1) AU2007287527B2 (ru)
BR (1) BRPI0716454A2 (ru)
CA (1) CA2661437A1 (ru)
CL (1) CL2007002422A1 (ru)
CO (1) CO6150139A2 (ru)
CR (1) CR10638A (ru)
EA (1) EA017917B1 (ru)
GB (1) GB0616574D0 (ru)
IL (1) IL196976A0 (ru)
MA (1) MA30672B1 (ru)
MX (1) MX2009001941A (ru)
NO (1) NO20090834L (ru)
PE (1) PE20080609A1 (ru)
TW (1) TW200825074A (ru)
WO (1) WO2008022994A1 (ru)
ZA (1) ZA200900886B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2070922E (pt) * 2004-02-23 2011-11-24 Glaxo Group Ltd Derivados de azabiciclo(3.1.0)hexano úteis como moduladores dos receptores d3 da dopamina
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
ATE484502T1 (de) * 2005-06-14 2010-10-15 Glaxo Group Ltd Neue verbindungen
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
ATE487715T1 (de) * 2005-08-22 2010-11-15 Glaxo Group Ltd Triazolderivate als modulatoren von dopamin-d3- rezeptoren
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
EP2007751B1 (en) * 2006-04-03 2013-08-21 Glaxo Group Limited Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
US8163927B2 (en) * 2006-04-03 2012-04-24 Glaxo Group Limited Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
WO2008153937A2 (en) * 2007-06-06 2008-12-18 Dov Pharmaceutical, Inc. Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
JP7250405B2 (ja) 2018-01-26 2023-04-03 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
AR127055A1 (es) 2021-09-14 2023-12-13 Lilly Co Eli Sales agonistas de sstr4

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4260941B2 (ja) * 1998-11-09 2009-04-30 株式会社片山製薬所 アゼチジン−３−オール
JP2002539194A (ja) * 1999-03-15 2002-11-19 ノボ ノルディスク アクティーゼルスカブ 新規の（２ｒ，３ｒ，４ｒ）−３，４−ジヒドロキシ−２−ヒドロキシメチルピロリジンの塩
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
PT2070922E (pt) * 2004-02-23 2011-11-24 Glaxo Group Ltd Derivados de azabiciclo(3.1.0)hexano úteis como moduladores dos receptores d3 da dopamina
SE526837C2 (sv) * 2004-02-24 2005-11-08 Kongsberg Automotive Asa Växelspakstransmission
CA2570634A1 (en) * 2004-06-30 2006-02-02 Eli Lilly And Company 1 (indole-6-carbonyl-d-phenylglycinyl) -4- (1-methylpiperidin-4-yl) piperazine d-tartrate
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use

Also Published As

Publication number Publication date
NO20090834L (no) 2009-03-19
WO2008022994A1 (en) 2008-02-28
CA2661437A1 (en) 2008-02-28
GB0616574D0 (en) 2006-09-27
AU2007287527B2 (en) 2013-01-31
CR10638A (es) 2009-03-20
US20080058398A1 (en) 2008-03-06
JP2010501519A (ja) 2010-01-21
CO6150139A2 (es) 2010-04-20
AR062471A1 (es) 2008-11-12
MX2009001941A (es) 2009-03-05
JP5315244B2 (ja) 2013-10-16
ZA200900886B (en) 2011-05-25
IL196976A0 (en) 2009-11-18
CL2007002422A1 (es) 2008-03-14
CN101528221B (zh) 2013-05-08
TW200825074A (en) 2008-06-16
BRPI0716454A2 (pt) 2014-03-04
AU2007287527A1 (en) 2008-02-28
CN101528221A (zh) 2009-09-09
KR101495362B1 (ko) 2015-02-24
KR20090052327A (ko) 2009-05-25
EA017917B1 (ru) 2013-04-30
PE20080609A1 (es) 2008-07-26
MA30672B1 (fr) 2009-08-03
EP2054054A1 (en) 2009-05-06

Similar Documents

Publication Publication Date Title
EA200970211A1 (ru) Применение производных азабициклогексана
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
DE602007009420D1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
EP1841426A4 (en) TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NZ590268A (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
EA200870569A1 (ru) Соединения и способы модуляции fxr
EA201791254A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
EA201200174A1 (ru) Производные оксазина и их применение в качестве ингибиторов bace для лечения неврологических нарушений
EA201001532A1 (ru) Соединения фенилзамещенного 2-имино-3-метилпирролопиримидинона в качестве ингибиторов bace-1, композиции и их применение
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
EA201100119A1 (ru) Химические соединения 251
EA200870599A1 (ru) Стабильные препараты лаквинимода
EA200801997A1 (ru) Новые соединения
UA97817C2 (ru) Гетероциклические производные 4-(метилсульфонил)фенила и их применение
EA200970156A1 (ru) Пиридизиноновые производные
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
MX2012002542A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
EA201001014A1 (ru) Фармацевтически приемлемые соли метил (3-{[[3-(6-амино-2-бутокси-8-оксо-7,8-дигидро-9h-пурин-9-ил)пропил](3-морфолин-4-илпропил)амино]метил}фенил)ацетата и их применение в терапии
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU